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1. Introduction 
The inhibitory role of GABA in certain central 
nervous system mechanisms is well known [ 1 ] . As 
GABA itself does not normally traverse the blood- 
brain barrier various inhibitors of GABA transaminase 
have been used in order to increase its cerebral level 
[2]. However, most of these inhibitors which cross 
the blood-brain barrier act on the coenzyme, 
pyridoxal phosphate, and hence are very toxic and. 
not specific for GABA-T. Some branched chain 
fatty acids inhibit purified GABA-T [3-51 as well 
as succinic semialdehyde dehydrogenase [6-71. 
We describe the results of experiments designed to 
explore the effect of inhibition of SSADH on GABA 
synthesis and degradation in a rat brain 900 X g 
supernatant fraction. 
2. Methods 
2.1. Preparation of/3H]SSA 
This was performed enzymatically. 20 c(g purified 
GABA-T from rat brain were incubated with [3H] 
GABA (1 pmol- 100 &i) and 3 X 1 O-“ 2-oxogluta- 
rate in 0.3 M Tris-HCI, pH 8.6, for 4 h at 37’C. The 
reaction was stopped by acidification to pH 2.0 with 
1 M HCI. One pmol of non radioactive SSA was added 
to the medium. This was obtained by hydrolysis of 
y-ethoxybutyrolactone in boiling water [8] and 
assayed as the 2-4 dinitrophenylhydrazone using a 
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solution of sodium pyruvate as a standard. The 
incubation medium (about 1 ml) was placed on a 1 cm 
by 4 cm column of Dowex 50 WX8, H+ form, eluted 
with distilled water and collected in 0.3 ml fractions. 
The SSA was detected in the fractions by the method 
of Salvador and Albers [9], whereby SSA reacts with 
3,5_diaminobenzoate under acid conditions to give a 
fluorescent quinaldehyde. The fractions containing 
SSA were pooled and assayed as indicated above. 
About 2 PCi of labelled SSA were obtained giving a 
yield of about 2%. 
2.2. Preparation of the 900 X g supematant fraction 
The brains of two adult Wistar rats, killed by 
decapitation, were rapidly removed and homogenised 
in 0.32 M sucrose at 4°C. After 5 min centrifugation 
at 900 X g, the supernatant was immediately employed 
for the incubation experiments in the presence of 
[jH] SSA. 
2.3. Incubation of the 900 X g supematantfiaction 
with SSADH inhibitors and / 3H]SSA 
For these experiments, 4 fractions of 200 11 (A, B, 
C and D) of the 900 X g supernatant fraction, con- 
taining 2.16 mg protein as determined by the Lowry 
method [lo] were preincubated in Potter micro- 
homogeniser tubes for 3 min at 37’C with 500 ~.tl of 
Krebs-Ringer solution, pH 7.4, using gentle agitation. 
The following compounds were added to a final 
concentration of 10 mM, to fractions A, B and C in 
10 ~1: (A) sodium dipropylacetate; (B) sodium 5,5- 
dipropylpentanoate; (C) sodium 2-propyl-2-penteno- 
ate. 10 ~.tl of Krebs-Ringer were added to fraction D, 
which served as a control. After a time lapse of 3 min 
to allow for temperature equilibration and diffusion 
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of inhibitors, 100 pl of [3H] SSA containing about 
0.3 nCi were added to each fraction. The concentration 
of SSA was thus 3.3 X 10e4 M in each fraction. The 
incubation was continued for 10 min at 37°C using 
gentle agitation and then the reaction was stopped by 
the addition of 200 ~1 of 1 M HCl. The precipitate 
of protein formed in the homogeniser tubes was 
homogenised with a Teflon-pestle and centrifuged for 
5minat 1OOOXg. 
2.4. Measurement of the specific activities of the r3H] 
GABA formed in each fraction 
After centrifugation, the supernatants were each 
placed on a 1 X 4 cm Dowex 50 WX8, H’ form, 
column, and rinsed with 15 ml distilled water. The 
amino compounds were eluted with 15 ml 2 M ammonia 
and the eluates lyophilised. The lyophilisates were 
redissolved in 0.5 ml of 0.2 M phosphate buffer, pH 
8.8, and dansylated according to the method of 
Zanetta et al. [ 111. The dansyl-amino compounds 
were separated by two-dimensional chromatography 
on thin-layer silica plates in the presence of dansyl- 
amino markers in both dimensions. This method 
permits isolation of the majority of dansyl-amino 
acids in a pure state. The spots corresponding to 
dansyl-GABA and dansyl-glutamate were scraped off 
the thin-layer plate and eluted as described by Zanetta. 
An aliquot of the eluate was taken to measure the 
fluorescence. Standard curves using pure solutions of 
dansyl-GABA and dansyl-glutamate were constructed 
in order to quantify the respective amino acids in 
the eluates. Other aliquots were used to measure 
radioactivity by scintillation counting. In all cases, 
controls were performed using eluates from silica gel 
samples where there were no spots. 
2.5. Measurement of the rate of GABA degradation 
An aliquot of 200 ~1 (No. l-7) of the 900 X g 
supernatant fraction containing 2.16 mg protein was 
preincubated as for the experiment with [3H]SSA. 
The following compounds were added respectively to 
fractions 1, 2 and 3 in 10 pl to a final concentration 
of 10 mM: (1) sodium dipropylacetate (2) sodium 5,5- 
dipropylpentanoate (3) sodium 2-propyl-2-pentenoate. 
10 pl of Krebs-Ringer was added to fraction 4, which 
served as a control. To fraction 5, p-hydroxybenzal- 
dehyde was added to a final concentration of 0.1 mM. 
This compound is a very potent inhibitor of SSADH 
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(competitive vis-&is SSA, Ki = 2.5 X 10e6 M). After 
a time lapse of 3 min for temperature equilibration, 
100 ~.tl of Krebs-Ringer solution was added to each 
fraction containing the following compounds (final 
concentration): GABA 2 mM, 2-ketoglutarate 0.5 mM, 
[U-r4C]GABA 5 pCi/ml, aminoethylisothiouronium 
bromide hydrobromide 1 mM, EDTA 0.1 mM, sodium 
succinate 0.02 mM, NAD 0.06 mM, pyridoxal phos- 
phate 0.5 mM. After 10 min incubation at 37”C, the 
reaction was stopped by addition of 200 ~1 of 10% 
trichloroacetic acid and the rate of degradation of 
GABA was measured as described by Dye and 
Taberner [ 121 in which the succinic acid product is 
eluted with 10 ml water from a Dowex 50 WX8, H’ 
form column. 
3. Results 
3.1. SSA as a precursor in GABA synthesis with and 
without branched chain fatty acid 
The GABA specific activities are expressed relatively 
to specific activity of the SSA considered as the pre- 
cursor (table 1). The radioactivity incorporated into 
glutamate is not significantly different from the back- 
ground counts. In table 2, we have reprinted the 
various Ki values vis-a-vis pure rat brain GABA-T 
and vis-a-vis purified rat brain SSADH [7] . The 
ratios of the Ki values: (Ki GABA-T/K, SSADH) give 
an indication of the relative importance of the 
inhibition of the two enzymes by the branched chain 
fatty acids. The absence of a significant level of radio- 
activity in the glutamate pool suggests that the radio- 
activity incorporated in GABA does not arise by 
metabolism of SSA via the Krebs cycle and decar- 
boxylation of glutamic acid. This radioactivity must 
thus be due to GABA-T activity. The presence of 
neither dipropylacetate nor 5,5-dipropyl-pentanoate 
modifies the quantity of labelled GABA formed. In 
the case of 2-propyl-2-pentenoate, a diminution of 
GABA synthesis from SSA is seen. This compound is 
the stronger inhibitor of GABA-T activity as shown 
by the measurement of the Ki with purified rat brain 
GABA-T [7] . 
3.2. Rate of degradation of GABA with or without 
branched chain fatty acids 
The activities measured in the presence or absence 
of the inhibitor are shown in table 3. The 3 branched 
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Table 1 
Level of incorporation of tritium in GABA with [ “HISSA as precursor, 
in the presence of various branched chain fatty acids 
Specific activity (GABA/SSA) 
Control 
Dipropylacetate 10 mM 
5,5-Dipropylpentanoate 10 mM 
2-Propyl-2-pentenoate 10 mM 
0.20 * 0.04 (4) 
0.17 * 0.06 (4) 
(n.s.) 
0.20 k 0.08 (4) 
(n.s.) 
0.081 f 0.023 (4) 
P < 0.01 
n.s. non significant 
Table 2 
Inhibition constants of some branched chain fatty acids for GABA-T and SSADH 
Ki GABA-T 
(10-s M) 
Ki SSADH 
(lo-’ M) 
Ki (GABA-T/SSADH) 
Dipropylacetate 9.5 4 2.7 
5,5-Dipropylpentanoate 6 0.3 20 
2-Propyl-2-pentenoate 0.5 4 0.12 
Table 3 
Rate of GABA degradation with and without branched chain fatty acid 
and a SSADH inhibitor 
GABA-T activity 
(lo+ mol/min) 
GABA-T activity 
(% decrease) 
Control 
DPA 10 mM 
2-Propyl-2-pentenoate 10 mM 
5,5-Dipropylpentanoate 10 mM 
4 Hydroxy benzaldehyde 0.1 mM 
0.319 f 0.012 
0.211 f 0.014 
P < 0.01 
0.193 f 0.015 
P < 0.01 
0.097 f 0.006 
P < 0.001 
0.297 f 0.004 
(n.s.) 
34% 
40% 
70% 
7% 
(n.s.) 
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chain fatty acids studied bring about a fall in GABA-T 
activity of at least 34% in the 900 X g supernatant 
from the rat brain homogenate. The concentration of 
GABA used for these studies (2 mM) is very close to 
the average in vivo level found in the rat brain. The 
concentration of fatty acids used (10 mM) is close 
to the cerebral level of DPA found in the rat brain 
after the i.p. injection of 200 mg/kg [ 131. This con- 
centration was determined using [i4C]DPA after it 
was shown that this compound is 70-80% unchanged 
in brain 60 min after its administration IP [ 141. 
As can be seen in table 3, the inhibition of SSADH, 
which is practically complete with lo4 M p-hydroxyl- 
benzaldehyde, does not significantly modify the rate 
of GABA degradation. 
4. Discussion 
Taking into account the cerebral concentration of 
SSA which is always very low, it cannot inhibit the 
degradation of GABA by GABA-T to a significant 
extent (competitive inhibition, Ki = 4 X 10m3 M, 
Maitre, unpublished results). As a result, inhibition of 
SSADH can only bring about an elevation in the 
GABA level by increasing the synthesis of GABA by 
GABA-T with SSA serving as a precursor. 
From these results, it can be seen that parallel 
inhibition of both GABA-T and SSADH does not 
produce an increase in the synthesis of GABA from 
SSA. In the case where the inhibitor was particularly 
strong vis-&is GABA-T, the GABA produced was 
actually less than in the control. However, in the 
presence of the concentrations of GABA and DPA 
existing in the rat brain 45 min after i.p. injection of 
200 mg/kg DPA [ 131, the rate of GABA degradation 
is reduced by 34% in comparison with the control. 
This effect is even greater with the inhibitors which 
are more potent such as 2-propyl-2-pentenoate and 
5,5-dipropyl-pentanoate. The almost complete inhibi- 
tion of SSADH by p-hydroxybenzaldehyde does not 
significantly affect the.rate of degradation of GABA. 
In the light of our results, it seems hardly likely 
that the increase of 30-45% in the cerebral GABA 
level in Swiss albino mice or Wistar rats after intra- 
peritoneal administration of 400 mg./kg of dipropyl- 
acetate [3,4] could be due to SSADH inhibition. 
Moreover, the relative specific activities of GABA-T 
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and SSADH in a brain homogenate is 1: 5 [7]. It is 
well known that the turnover rate of a NAD linked 
dehydrogenase is considerably greater than that of a 
transaminase, particularly GABA-T [ 15,161. 
Consequently, the cerebral SSA level is always very 
low. Under normal conditions, the limiting factor 
in GABA degradation to succinic acid is thus GABA-T 
activity. With dipropylacetate and 2-propyl-2-penteno- 
ate, taking into account the respective Ki values for 
SSADH and GABA-T, the limiting activity for 
accumulation of GABA is GABA-T. In the case of 
5,5dipropylpentanoate, the residual SSADH activity 
is inferior to that of GABA-T. Despite this, the level of 
SSA incorporation into GABA is not significantly 
modified in relation to the control. These experiments 
confirm those of Baxter and Roberts [ 171 which show 
the impossibility of raising cerebral GABA levels after 
inhibition of SSADH in vivo by various inhibitors 
including analogues of NAD. 
Anlezark et al. [18] report the absence of inhibi- 
tion of GABA-T in a rat brain homogenate containing 
2 or 5 mM GABA, by 5-15 mM DPA. This result can 
be explained by the fact that the method used 
(measurement of [‘*Cl glutamate formed from [‘“Cl 
2-oxoglutarate in the presence of 20 mg of cerebral 
tissue) does not allow the unique measurement of 
GABA-T activity, but the sum of the enzymatic 
activities which transform 2-oxoglutarate into gluta- 
‘mate, particularly aspartate aminotransferase activity 
which is very high in comparison to GABA-T activity, 
and uses the aspartate endogenous to the tissue 
fraction. Moreover, GABA-T activity was measured in 
the presence of an inhibitory concentration of 
2-oxoglutarate (25 mM). As this inhibition is competi, 
tive with respect to GABA [ 151 which was present at 
low concentrations (2 and 5 mM), the conditions are 
not ideal to measure the effect of a second inhibitor 
(DPA) in the incubation medium. 
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